Company Overview and News
Akoustis claims that its single-crystal BAW filters can offer better performance than the BAW filters currently marketed by industry leaders Broadcom and Qorvo in emerging 3GHz+ applications.
QRVO AVGO AKTS
2018-09-19 investorplace - 2
Workers in their 30s and 40s often find themselves in tricky situations, career-wise. They’re certainly beyond their trainee days, but not yet in positions only awarded to employees with a wealth of experience and proven acumen. It’s in this time of life when workers find themselves on a clear path to some sort of senior position, or realize it’s just not going to happen.
QRVO MA PYPL AMD NVDA WMT ADBE AMZN AMT MRK GOOGL MSFT CAH INTC
2018-09-13 investorplace - 2
Pot stocks like Canopy Growth Corp (NYSE:CGC) have been on absolute fire lately. Are pot stocks becoming the next crypto-craze, dare we say? I don’t know if I’d go that far with Canopy Growth stock, but its ascent has surely attracted plenty of attention.
STZ.B QRVO TWLO DBX WEED BOX M STZ CGC BB TLRY CMG
Concerns over Trump’s protectionist trade stance have been playing foul in the stock market. In fact, the escalation of the President’s tariff threat on additional Chinese goods led to a tumultuous Wall Street ride last week. However, the negative sentiments seem to be reversing, given the hopes of fresh talks between the United States and China (read: 5 Inverse Leveraged ETFs Off to a Strong Start in September).
QRVO BOE BA OXY
Qorvo, Inc. (QRVO - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at QRVO given that, according to its RSI reading of 27.81, it is now in oversold territory.
2018-09-06 marketwatch - 2
Chip-related stocks got pummeled for their worst day in nearly two months Thursday after market outlooks from a few key players proved to be weaker than previously forecast.
MRVL LRCX QRVO TER MU ENTG AMAT MKSI AMD
Qorvo, Inc. (QRVO - Free Report) has demonstrated impressive price performance over the last two years. The stock, which was valued at $40 at the beginning of February2016, now currently trades close to $80.1, reflecting an almost two-fold jump. Year to date, shares of Qorvo have returned approximately 20.2% substantially outperforming the industry’s rally of 1.1%. In the same period, the stock has also fared better than the S&P 500 index’s rise of 10.
QRVO AZPN PAYC
Qorvo, Inc. (QRVO - Free Report) concluded the previously announced private offering of $130 million principal amount of 5.50% Senior Notes due 2026. These additional notes once placed will be an unsecured senior liability of Qorvo. Notably, interest for these additional notes will be paid semi-annually.
QRVO MLNX URBN AZPN
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")[email protected],0G2P8F1H8#(%D&1G3B/^/D/P [email protected]"T5 ;D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
The U.S. bull market has now become the longest on record since World War II by avoiding a drop of 20% or more (the traditional definition of a bear market). Its run of 3,453 days or nine and-a-half years outpaced the 3,452-day record set during Sep 11, 1990 to Mar 24, 2000. Though this bull run is the longest ever, it is the second powerful with gains of 324% for the S&P 500, just behind the 417% rally seen during the 1990-2000 run.
QRVO REGN AMZN AAPL SIVB
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET